NEW YORK, Nov. 20, 2023 /PRNewswire/ — (PRNEWSWIRE) Pomerantz LLP is investigating claims on behalf of investors of Cano Health, Inc. (“Cano” or the “Company”) (NYSE: CANO). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
The investigation concerns whether Cano and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On November 17, 2023, UBS cut its rating of Cano Health to “Sell”, citing the Company’s deteriorating liquidity position. UBS opined that “elevated third-party medical expenses will have a sustained negative effect on the company’s already challenged liquidity position.”
On this news, Cano’s stock price fell $0.55 per share or 6.72%, to close at $7.63 per share on November 17, 2023.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:Robert S. Willoughby
Pomerantz LLP
[email protected]
888-476-6529 ext. 7980
SOURCE Pomerantz LLP